NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy
Published date:
11/13/2022
Excerpt:
Sixteen stage IV NSCLC patients with uncommon EGFR mutations from 9 different German centers were treated in first or further line with Atezolizumab, Bevacizumab, Carboplatin and (nab-)Paclitaxel (ABCP)….Median PFS was 13.6 months for both the entire cohort and for Exon 20 insertions.